 CAMBRIDGE, Mass.--BUSINESS WIRE--Acceleron Pharma Inc. Nasdaq:XLRN, a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL luspatercept-aamt as reported by its global collaborator, Bristol Myers Squibb, were approximately 128 million for the second quarter ended June 30, 2021. Acceleron expects to report royalty revenue of approximately 25.6 